Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, shows significant benefit among patients with EGFR T790M mutation at disease progression. We analyzed the whole exome sequence of 48 samples obtained from 16 lung cancer patients with a longitudinal follow-up: treatment-naïve-baseline p...

書誌詳細
出版年:	Translational Oncology
主要な著者:	Asim Joshi, Ashwin Butle, Supriya Hait, Rohit Mishra, Vaishakhi Trivedi, Rahul Thorat, Anuradha Choughule, Vanita Noronha, Kumar Prabhash, Amit Dutt
フォーマット:	論文
言語:	英語
出版事項:	Elsevier 2022-08-01
主題:	Erlotinib resistance Low allele fraction EGFR T790M Osimertinib Orthotopic lung cancer mice model Bioluminescence imaging Next generation sequencing
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S1936523322001206

類似資料

Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs
著者:: Ashwin Butle, 等
出版事項: (2021-08-01)

Primary resistance to osimertinib despite acquired T790M
著者:: Ling‐Kai Chang, 等
出版事項: (2020-03-01)

A patient with a lung adenosquamous carcinoma harboring a de novo T790M mutation and huge nonbacterial vegetative growths successfully treated with osimertinib: A case report
著者:: So‐yun Kim, 等
出版事項: (2023-06-01)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
著者:: Hanping Wang, 等
出版事項: (2020-03-01)

Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib
著者:: Yubo Wang, 等
出版事項: (2022-04-01)

Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment
著者:: Ulrich Jarry, 等
出版事項: (2021-05-01)

Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report
著者:: Diego Enrico, MD, 等
出版事項: (2023-02-01)

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy
著者:: Isa Mambetsariev, 等
出版事項: (2018-03-01)

OPTIMAL SEQUENCE OF APPLICATION OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVATING EGFR MUTATIONS
著者:: A. A. Kolomeytseva, 等
出版事項: (2020-12-01)

The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis
著者:: Liuxian Guo, 等
出版事項: (2024-04-01)

T790M mutation and clinical outcomes with osimertinib in patients with epidermal growth factor receptor-mutant nonsmall cell lung cancer
著者:: Ravi Jaiswal, 等
出版事項: (2019-01-01)

Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M‐positive: Case report and literature review
著者:: Chihiro Maeda, 等
出版事項: (2023-10-01)

Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example
著者:: Bing Wei, 等
出版事項: (2019-05-01)

Complete response in a lung adenocarcinoma with pleural metastases initially treated with gefitinib and switched to osimertinib after cerebral oligo-progression with unknown T790M mutation: a case report and review of literature
著者:: Mariem Hachlaf, 等
出版事項: (2024-08-01)

SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness
著者:: Leiming Xia, 等
出版事項: (2021-07-01)

Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis
著者:: Xinyue Wang, 等
出版事項: (2025-04-01)

Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer
著者:: Maria Gabriela O. Fernandes, 等
出版事項: (2021-05-01)

Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease
著者:: Molly S.C. Li, M.B.B.S., 等
出版事項: (2024-04-01)

Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
著者:: Asako Matsuda, 等
出版事項: (2019-12-01)

Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations
著者:: Yingxue Li, 等
出版事項: (2024-08-01)

ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial–mesenchymal transition
著者:: Kejun Liu, 等
出版事項: (2021-05-01)

Synergistic Enhancement of Osimertinib Efficacy in Non-small Cell Lung Cancer Cells Through Epigallocatechin-3-Gallate: Mechanistic Insights Into YAP/TEAD/CTGF Axis Inhibition
著者:: Ashwini Somayaji, 等
出版事項: (2025-07-01)

SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
著者:: Luwei Han, 等
出版事項: (2021-04-01)

Different Clinicopathologic and Computed Tomography Imaging Characteristics of Primary and Acquired EGFR T790M Mutations in Patients with Non-Small-Cell Lung Cancer
著者:: Hou D, 等
出版事項: (2021-08-01)

Osimertinib Did Not Respond to a Pulmonary Adenocarcinoma with Triple Mutations of Epidermal Growth Factor Receptor, G719S, T790M and S768I
著者:: Seigo Minami, 等
出版事項: (2019-02-01)

Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation
著者:: Shanliang Hu, 等
出版事項: (2022-08-01)

Next-generation sequencing-based detection in a breast MMPMN patient with EGFR T790M mutation: a rare case report and literature review
著者:: Huiyun Lv, 等
出版事項: (2023-07-01)

Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review)
著者:: O.M. Smorodska, 等
出版事項: (2021-06-01)

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
著者:: Jae Cheol Lee, 等
出版事項: (2021-05-01)

Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control
著者:: Ha-Lim Jeon, 等
出版事項: (2024-06-01)

Osimertinib-Induced Hepatitis Following Immunotherapy in a Patient with Lung Adenocarcinoma Harboring De Novo EGFR Exon 19 Deletion and T790M Mutations: A Case Report
著者:: Bradley Steiner, 等
出版事項: (2025-06-01)

A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)
著者:: Kazushige Wakuda, 等
出版事項: (2020-05-01)

Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib
著者:: Ying Jin, 等
出版事項: (2022-05-01)

Osimertinib in NSCLC: Real-World Data From New Zealand
著者:: Yeojeong Jane So, MbChB, FRACP, 等
出版事項: (2020-06-01)

Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report
著者:: Yuri Taniguchi, 等
出版事項: (2018-05-01)

Nanocage-incorporated engineered destabilized 3'UTR ARE of ERBB2 inhibits tumor growth and liver and lung metastasis in EGFR T790M osimertinib- and trastuzumab-resistant and ERBB2-expressing NSCLC via the reduction of ERBB2
著者:: Chidiebere U. Awah, 等
出版事項: (2024-04-01)

Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis
著者:: Taisuke Ito, 等
出版事項: (2024-01-01)

Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
著者:: Hardy Niu, 等
出版事項: (2017-09-01)

Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer
著者:: Jacqueline V. Aredo, 等
出版事項: (2022-01-01)

Osimertinib as Salvage Therapy in Advanced Non‐Small Cell Lung Cancer After Aumolertinib Resistance With T790M Mutation: A Case Report
著者:: Yongtong Tang, 等
出版事項: (2025-02-01)